Chiusura precedente | 4,93 |
Aperto | 4,97 |
Denaro | 5,64 x 200 |
Lettera | 5,70 x 200 |
Min-Max giorno | 4,97 - 6,13 |
Intervallo di 52 settimane | 2,01 - 6,13 |
Volume | |
Media Volume | 943.316 |
Capitalizzazione | 344,386M |
Beta (5 anni mensile) | 0,95 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,78 |
Prossima data utili | 13 mag 2024 - 17 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 13,78 |
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs,
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Citi 18th Annual BioPharma ConferenceFormat: Fireside ChatDate: Wednesday, September 6, 2023Time: 8:00 a.m. ET / 5:00 a.m. PT Locat
- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 - - Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to a